Announcements
- Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
- Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
- Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
- Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
- Lisata Therapeutics to Present at BIO CEO & Investor Conference
- Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
- Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
More ▼
Key statistics
On Friday, Lisata Therapeutics Inc (8NE:DUS) closed at 2.42, 35.96% above the 52 week low of 1.78 set on Sep 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.70 |
---|---|
High | 2.70 |
Low | 2.38 |
Bid | 2.44 |
Offer | 2.76 |
Previous close | 2.52 |
Average volume | 0.00 |
---|---|
Shares outstanding | 8.31m |
Free float | 6.75m |
P/E (TTM) | -- |
Market cap | 23.68m USD |
EPS (TTM) | -2.58 USD |
Data delayed at least 15 minutes, as of May 03 2024 18:32 BST.
More ▼